Drug Profile
Research programme: nuclear receptor-targeting therapeutics - Genfit
Alternative Names: AD Inov collaborative programme; G-15750; TGFTX1; TGFTX3Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator Genfit
- Class Small molecules
- Mechanism of Action Cytoplasmic and nuclear receptor modulators; Nuclear receptor subfamily 1 group F member 3 antagonists; Peroxisome proliferator-activated receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Autoimmune disorders; Cardiovascular disorders; Hepatic fibrosis; Metabolic disorders; Psoriasis; Respiratory tract disorders
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Psoriasis in France (Topical)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Respiratory-tract-disorders in France (Inhalation)
- 28 May 2020 No recent reports of development identified for preclinical development in Hepatic-fibrosis in France